Literature DB >> 9205091

Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.

V M Richon1, P Russo, G Venta-Perez, C Cordon-Cardo, R A Rifkind, P A Marks.   

Abstract

Many transformed cells have been found to lose the capacity to proliferate and undergo differentiation following exposure to hybrid polar agents. This study investigates the mechanism by which hexamethylene bisacetamide (HMBA) suppresses the proliferation of the human bladder carcinoma line, T24. We found that following a 24-h exposure to HMBA, T24 proliferation was inhibited, and cells arrested in G1 phase and underwent morphological maturation. HMBA-induced cessation of proliferation was mediated, in part, by effects on cell cycle regulatory proteins. In T24 cells cultured without HMBA, E2F complexes predominantly with p107. In culture with inducer, p107 protein decreased, pRB and p130 were converted to underphosphorylated forms, and E2F was shifted into complexes with pRB and p130. To determine whether the formation of pRB:E2F and p130:E2F complexes was required for the HMBA-induced G1 arrest, the ability of the pocket proteins to bind E2F was blocked by enforced expression of human papillomavirus 16 E7. Following culture with HMBA, the T24 clones expressing E7 died, whereas vector-alone T24 clones arrested in G1 phase. T24/E7-1 cells did not form pRB:E2F or p130:E2F complexes upon culture with HMBA; rather, E2F was present in its free form. T24/E7-1 cells cultured with HMBA initially accumulate in G1. By day 2, they have entered into S phase, and by day 3, over 80% of the cells became apoptotic. Taken together, these studies enlarge the repertoire of demonstrated developmental pathways that may be triggered in transformed cells, depending upon their molecular status, and may provide potential therapeutic opportunities for cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205091

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

2.  Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.

Authors:  D S Siegel; X Zhang; R Feinman; T Teitz; A Zelenetz; V M Richon; R A Rifkind; P A Marks; J Michaeli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

3.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Histone deacetylase inhibitors: clinical implications for hematological malignancies.

Authors:  Francesco Paolo Tambaro; Carmela Dell'aversana; Vincenzo Carafa; Angela Nebbioso; Branka Radic; Felicetto Ferrara; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2010-07-28       Impact factor: 6.551

5.  Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth.

Authors:  T K Said; R C Moraes; R Sinha; D Medina
Journal:  Breast Cancer Res       Date:  2000-12-22       Impact factor: 6.466

6.  Hexamethylene bisacetamide impairs NK cell-mediated clearance of acute T lymphoblastic leukemia cells and HIV-1-infected T cells that exit viral latency.

Authors:  Erica Giuliani; Maria Giovanna Desimio; Margherita Doria
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

Review 7.  Photoaffinity labeling in target- and binding-site identification.

Authors:  Ewan Smith; Ian Collins
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.